scholarly journals Profile and evolution of the chemosusceptibility of falciparum malaria imported into France in 2000

2002 ◽  
Vol 7 (7) ◽  
pp. 113-118 ◽  
Author(s):  
P Ralaimazava ◽  
R Durand ◽  
N Godineau ◽  
A Keundjian ◽  
Z Jezic ◽  
...  

In 2000, the chemosusceptibility of imported malaria was stable in France. All countries of infection considered, the bi-resistance to chloroquine and cycloguanil has not changed from 1996 to 2000. The monotherapy using quinine or mefloquine remains the first-line treatment to falciparum malaria. Resistance to these two antimalarials is rare in Africa and has not evolved over the past 15 years.

2008 ◽  
Vol 5 (3) ◽  
pp. 71-73
Author(s):  
Haroon Rashid Chaudhry ◽  
Nadia Arshad ◽  
Saima Niaz ◽  
Tahir Suleman ◽  
Khalid A. Mufti

Schizophrenia is a chronic illness with a lifetime prevalence of 1% and with serious physical, social and economic consequences. Over the past decade, atypical antipsychotic medications have become the first-line treatment for schizophrenia (Breier et al, 2005).


BMJ ◽  
2004 ◽  
Vol 328 (7439) ◽  
pp. 545 ◽  
Author(s):  
Christopher V Plowe ◽  
James G Kublin ◽  
Fraction K Dzinjalamala ◽  
Deborah S Kamwendo ◽  
Phillips Chimpeni ◽  
...  

2009 ◽  
Vol 13 (5) ◽  
pp. 266-272 ◽  
Author(s):  
Navid Ezra ◽  
Joseph F. Greco ◽  
Jennifer C. Haley ◽  
Melvin W. Chiu

Background: Phymas are slowly progressive, disfiguring disorders of the face and ears that represent the end stage of rosacea. The most common phyma is rhinophyma, yet similar swellings may occur on the chin (gnatophyma), forehead (metophyma), one or both ears (otophyma), and eyelids (blepharophyma). Objective: Unlike rhinophyma, otophyma is rarely seen. We report two rare phymas: a case of gnatophyma and a case of otophyma. Methods: A 56-year-old African American man presented with a history of bumps on his chin that had begun about 7 years earlier. Physical examination was remarkable for lobulated plaques on the chin, coalescing into hypertrophic nodules and dilated pores. A 73-year-old African American male presented with bilateral cauliflower-like earlobe growths for the past 17 years. Results: A skin biopsy was performed for each patient demonstrating cystic follicular dilatation with keratin plugging, dermal scarring, psoriasiform epidermal hyperplasia, and chronic inflammation of some of the follicles. Conclusion: This case report describes a relatively rare gnatophyma and otophyma. Surgical management is well accepted as the best mode of therapy to treat rhinophyma and is becoming a first-line treatment for all phymas.


2019 ◽  
Vol 11 (1) ◽  
pp. 88-96 ◽  
Author(s):  
Wu Zou ◽  
Fuchun Gong ◽  
Zhong Cao ◽  
Jiaoyun Xia ◽  
Tingting Gu ◽  
...  

Artemisinin (ART) and its derivatives are first-line treatment drugs for falciparum malaria and save millions of lives every year. A VB1-based fluorogenic probe for ART determination was developed by measuring the products of VB1 oxidized by ART.


Hematology ◽  
2005 ◽  
Vol 2005 (1) ◽  
pp. 285-291
Author(s):  
Michael Hallek ◽  

For the past ten years, there has been a dynamic development of new therapeutic compounds and prognostic parameters for chronic lymphocytic leukemia (CLL). Hematologists and oncologists are challenged to use these new possibilities for an optimized, risk- and fitness-adapted treatment strategy, with the goal of achieving long-term remissions and preserving a good quality of life. This review is intended to summarize the current knowledge on first-line treatment of CLL.


2016 ◽  
Vol 10 (11-12) ◽  
pp. 245 ◽  
Author(s):  
Christian Kollmannsberger

With the proliferation of treatment options for the management of metastatic renal cell carcinoma (mRCC) over the past decade, predictive markers of response to therapy are becoming increasingly important. Sunitinib is commonly used in the first-line treatment of mRCC. Common mechanism-based adverse events, including hypertension, hypothyroidism, hand-foot syndrome, and neutropenia, have been explored as potential biomarkers of the clinical efficacy of sunitinib in mRCC and are reviewed in this article.


Hematology ◽  
2005 ◽  
Vol 2005 (1) ◽  
pp. 285-291 ◽  
Author(s):  
Michael Hallek ◽  

Abstract For the past ten years, there has been a dynamic development of new therapeutic compounds and prognostic parameters for chronic lymphocytic leukemia (CLL). Hematologists and oncologists are challenged to use these new possibilities for an optimized, risk- and fitness-adapted treatment strategy, with the goal of achieving long-term remissions and preserving a good quality of life. This review is intended to summarize the current knowledge on first-line treatment of CLL.


Sign in / Sign up

Export Citation Format

Share Document